Ibrance

Ibrance is a prescription medication used in the treatment of certain types of breast cancer. It is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor, specifically targeting proteins involved in cell cycle progression. Developed and marketed by Pfizer, it is indicated in combination with other agents for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Medical uses

Ibrance is approved by the U.S. Food and Drug Administration and the European Medicines Agency for use in postmenopausal women, and in men, with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor like letrozole as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed after endocrine therapy. The pivotal PALOMA-2 and PALOMA-3 clinical trials demonstrated significant improvement in progression-free survival for patients receiving these combinations compared to endocrine therapy alone. Its use is not indicated for patients with visceral crisis.

Adverse effects

The most common adverse reactions associated with Ibrance include neutropenia, leukopenia, fatigue, anemia, nausea, stomatitis, alopecia, diarrhea, and thrombocytopenia. Severe neutropenia is a frequent and serious side effect, requiring regular monitoring of complete blood counts. Other notable risks include pulmonary embolism and interstitial lung disease. Patients are advised to report signs of infection or respiratory symptoms promptly. The drug carries a Pregnancy Category D rating due to potential fetal harm.

Pharmacology

Ibrance contains the active pharmaceutical ingredient palbociclib, a selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). These kinases, when activated by cyclin D1, promote cell cycle progression from the G1 phase to the S phase by phosphorylating and inactivating the retinoblastoma (Rb) tumor suppressor protein. By inhibiting CDK4/6, palbociclib induces cell cycle arrest, preventing cellular proliferation in hormone receptor-positive breast cancer cells. It is administered orally and is metabolized primarily in the liver by the CYP3A and SULT2A1 enzymes, with a terminal half-life of approximately 29 hours.

History

The development of palbociclib originated from research at Onyx Pharmaceuticals and later Pfizer, which acquired the global rights. The drug received its first regulatory approval from the U.S. Food and Drug Administration in February 2015 under the agency's Breakthrough Therapy designation, based on data from the PALOMA-1 trial. This accelerated approval was for use with letrozole in postmenopausal women with ER-positive, HER2-negative advanced breast cancer. Full approval was subsequently granted in March 2017 following confirmatory results from the PALOMA-2 study. The European Commission granted marketing authorization in November 2016.

Society and culture

Ibrance has had a significant impact on the treatment paradigm for hormone receptor-positive metastatic breast cancer, becoming a standard of care. Its high cost has been a subject of discussion within healthcare systems, including debates over formulary coverage by insurers and programs like Medicare. The drug has been featured in media reports by outlets such as The New York Times highlighting advances in cancer therapy. Patient assistance programs are offered by Pfizer to improve access. The development of palbociclib also spurred further research into other CDK4/6 inhibitors, such as ribociclib and abemaciclib.

Category:Drugs